Cargando…

FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription

Androgen/AR is the primary contributor to prostate cancer (PCa) progression by regulating Prostate Specific Antigen (PSA) gene transcription. The disease inevitably evolves to androgen-independent (AI) status. Other mechanisms by which PSA is regulated and develops to AI have not yet been fully dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Youhong, Liu, Yijun, Yuan, Bowen, Yin, Linglong, Peng, Yuchong, Yu, Xiaohui, Zhou, Weibing, Gong, Zhicheng, Liu, Jianye, He, Leye, Li, Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370019/ https://www.ncbi.nlm.nih.gov/pubmed/28199985 http://dx.doi.org/10.18632/oncotarget.15224

Ejemplares similares

AB033. Novel roles of mitochondrial outer membrane proteins in the maintenance of androgen receptor protein stability, resistance to anti-androgen receptor agents and progression of prostate cancer
por: Ying, Linglong, et al.
Publicado: (2016)

The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
por: Hou, Youxiang, et al.
Publicado: (2017)

FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness
por: Yuan, Bowen, et al.
Publicado: (2018)

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018)

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2022)

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
por: Fu, Yongming, et al.
Publicado: (2023)

Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition
por: Yu, Xiaohui, et al.
Publicado: (2018)

FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription
por: Hou, Youxiang, et al.
Publicado: (2022)

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer
por: Yin, Linglong, et al.
Publicado: (2023)

USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis
por: Peng, Yuchong, et al.
Publicado: (2019)

Aberrant ASPM expression mediated by transcriptional regulation of FoxM1 promotes the progression of gliomas
por: Zeng, Wen‐Jing, et al.
Publicado: (2020)

Novel Interactions between FOXM1 and CDC25A Regulate the Cell Cycle
por: Sullivan, Con, et al.
Publicado: (2012)

SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription
por: Yang, Liu, et al.
Publicado: (2020)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability
por: Peng, Yuchong, et al.
Publicado: (2023)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Transcriptional regulation of FoxM1 by HIF-1α mediates hypoxia-induced EMT in prostate cancer
por: Tang, Cong, et al.
Publicado: (2019)

PSA mass as a marker of prostate cancer progression after radical prostatectomy
por: Bryniarski, Piotr, et al.
Publicado: (2011)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma
por: Fei, Wei, et al.
Publicado: (2023)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

E2F2 promotes lung adenocarcinoma progression through B-Myb- and FOXM1-facilitated core transcription regulatory circuitry
por: Du, Kailong, et al.
Publicado: (2022)

Anacardic acid induces cell apoptosis of prostatic cancer through autophagy by ER stress/DAPK3/Akt signaling pathway
por: Tan, Jing, et al.
Publicado: (2017)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Role of transcription factor FOXM1 in diabetes and its complications (Review)
por: Zhao, Baoqing, et al.
Publicado: (2023)

Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells
por: Liu, Youhong, et al.
Publicado: (2014)

Aberrantly high activation of a FoxM1–STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers
por: Liu, Jun, et al.
Publicado: (2021)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer
por: Pan, Huafeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p2l2bkbcpih5eko4at00inq0av